Future experimentation in other in vitro models of breast cancer as well as in vivo mouse mammary models could determine the toxicity of these compounds, their utility in treating BRCA1 wild-type tumors, and the value of these compounds in the treatment of PARPi-resistant tumors that have undergone reversion mutations. The gene discussed is BRCA1; the disease is breast carcinoma.